Cellectis said on Monday that AstraZeneca had finalized its additional $140 million investment in the company, in line with the deal announced last November.

The biotech company, which specializes in immunotherapies, said that completion of the transaction followed approval from the French Ministry of the Economy and the satisfaction of other conditions precedent.

As part of the transaction, AstraZeneca today subscribed for ten million "Class A" preference shares and 18 million "Class B" shares, both at a unit price of five dollars per share.

As a result, the pharmaceutical giant now holds 44% of the capital and 30% of the voting rights of Cellectis, which will enable it to obtain two seats on the Board of Directors with the addition of Marc Dunoyer and Dr. Tyrell Rivers to the body.

As part of their collaboration, AstraZeneca intends to draw on Cellectis' gene-editing technologies to design new cell-based cancer therapies.

In detail, 25 genetic targets have been exclusively reserved for AstraZeneca, from which up to 10 product candidates could be explored for development.

Following these announcements, Cellectis shares rose by over 6% on Monday on the Paris Bourse, bringing their gains over the past 12 months to over 68%.

Copyright (c) 2024 CercleFinance.com. All rights reserved.